Benefit Also in Early Stage: Olaparib in BRCA+ Breast Cancer Benefit Also in Early Stage: Olaparib in BRCA+ Breast Cancer

Patients taking olaparib had a 42% reduction in the risk of local recurrence of breast cancer, metastatic recurrence of breast cancer, other new cancers, or death due to any cause.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news